Autoimmunity in atherosclerosis: lessons from experimental models

被引:43
作者
George, J
Afek, A
Gilburd, B
Harats, D
Shoenfeld, Y
机构
[1] Tel Aviv Univ, Sackler Fac Med, Chaim Sheba Med Ctr, Dept Med B, IL-69978 Tel Aviv, Israel
[2] Tel Aviv Univ, Sackler Fac Med, Chaim Sheba Med Ctr, Autoimmune Dis Res Unit, IL-69978 Tel Aviv, Israel
[3] Tel Aviv Univ, Sackler Fac Med, Chaim Sheba Med Ctr, Inst Pathol, IL-69978 Tel Aviv, Israel
关键词
atherosclerosis; antiphospholipid antibodies; autoimmunity; beta 2-glycoprotein I; HSP; 60/65; oxLDL;
D O I
10.1191/096120300678828190
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The modern view of atherosclerosis is of a chronic inflammatory disorder. In accord with this paradigm, the process of uninhibited influx of fat to the vessel wall results from an 'adequate' response to various forms of injury (i.e. turbulence, infections, modified lipoproteins). This idea has been further extended by several groups, to assume that the atherosclerotic lesion can be the target of an autoimmune mediated attack. According to this hypothesis, the site of initiation of the plaque should bear/express the target autoantigen, whereas concomitantly a respective immune response is generated in the periphery. The examples illuminating this notion are beta 2GPI as a target autoantigen, HSP60/65 an oxidized-LDL. Herein we present evidence to support the involvement of autoimmune mechanisms in atherogenesis based on the experience from experimental models and human studies.
引用
收藏
页码:223 / 227
页数:5
相关论文
共 38 条
  • [1] Enhancement of atherosclerosis in beta-2-glycoprotein I-immunized apolipoprotein E-deficient mice
    Afek, A
    George, J
    Shoenfeld, Y
    Gilburd, B
    Levy, Y
    Shaish, A
    Keren, P
    Janackovic, Z
    Goldberg, I
    Kopolovic, J
    Harats, D
    [J]. PATHOBIOLOGY, 1999, 67 (01) : 19 - 25
  • [2] PATIENTS WITH EARLY-ONSET PERIPHERAL VASCULAR-DISEASE HAVE INCREASED LEVELS OF AUTOANTIBODIES AGAINST OXIDIZED LDL
    BERGMARK, C
    WU, R
    DEFAIRE, U
    LEFVERT, AK
    SWEDENBORG, J
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1995, 15 (04) : 441 - 445
  • [3] Infectious agents and atherosclerotic vascular disease
    Cook, PJ
    Lip, GYH
    [J]. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 1996, 89 (10) : 727 - 735
  • [4] PROTEINS AS MOLECULAR CHAPERONES
    ELLIS, J
    [J]. NATURE, 1987, 328 (6129) : 378 - 379
  • [5] Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes
    Freigang, S
    Hörkkö, S
    Miller, E
    Witztum, JL
    Palinski, W
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1998, 18 (12) : 1972 - 1982
  • [6] Differential effects of anti-β2-glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome
    George, J
    Blank, M
    Levy, Y
    Meroni, P
    Damianovich, M
    Tincani, A
    Shoenfeld, Y
    [J]. CIRCULATION, 1998, 97 (09) : 900 - 906
  • [7] Enhanced fatty streak formation in C57BL/6J mice by immunization with heat shock protein-65
    George, J
    Shoenfeld, Y
    Afek, A
    Gilburd, B
    Keren, P
    Shaish, A
    Kopolovic, J
    Wick, G
    Harats, D
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (03) : 505 - 510
  • [8] Atherosclerosis in LDL-receptor knockout mice is accelerated by immunization with anticardiolipin antibodies
    George, J
    Afek, A
    Gilburd, B
    Levy, Y
    Blank, M
    Kopolovic, J
    Harats, D
    Shoenfeld, Y
    [J]. LUPUS, 1997, 6 (09) : 723 - 729
  • [9] Immunolocalization of β2 glycoprotein I (apolipoprotein H) to human atherosclerotic plaques -: Potential implications for lesion progression
    George, J
    Harats, D
    Gilburd, B
    Afek, A
    Levy, Y
    Schneiderman, J
    Barshack, I
    Kopolovic, J
    Shoenfeld, Y
    [J]. CIRCULATION, 1999, 99 (17) : 2227 - 2230
  • [10] Oxidized low-density lipoprotein (Ox-LDL) but not LDL aggravates the manifestations of experimental antiphospholipid syndrome (APS)
    George, J
    Blank, M
    Hojnik, M
    BarMeir, E
    Koike, T
    Matsuura, E
    Lorber, M
    Aviram, M
    Shoenfeld, Y
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1997, 108 (02) : 227 - 233